A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
The study is conducted in two phases, The phase I is the dose exploration phase, and the phase II is the dose expansion phase. The phase I clinical trial is to select an acceptable safe dose for the phase II clinical trial to further determine safety, pharmacokinetics and efficacy of this combinatio...
The study is conducted in two phases, The phase I is the dose exploration phase, and the phase II is the dose expansion phase. The phase I clinical trial is to select an acceptable safe dose for the phase II clinical trial to further determine safety, pharmacokinetics and efficacy of this combination regimen in patients with specific tumor types.
Tracking Information
- NCT #
- NCT04472858
- Collaborators
- CStone Pharmaceuticals
- Investigators
- Principal Investigator: Ye Guo, MD Shanghai East Hospital
Get Well Soon